Intravesical chemotherapy: An update - New trends and perspectives

EAU Update Series

Volumn 1, Issue 2, 2003, Pages 71-79

  Van Der Heijden, A G ^a   Witjes, J A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chemotherapeutic instillation; Doxorubicin; Epirubicin; Gemcitabin; Intravesical hyperthermia; Mitomycin C; Pirarubicin; Review; Superficial bladder cancer; Valrubicin

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; DOXORUBICIN; EPIRUBICIN; ETOGLUCID; GEMCITABINE; MITOMYCIN C; PIRARUBICIN; THIOTEPA; VALRUBICIN;

ALLERGIC REACTION; BLADDER CARCINOMA; BONE MARROW SUPPRESSION; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER MODEL; CORRELATION ANALYSIS; CYSTITIS; CYTOTOXICITY; DILUTION; DISEASE COURSE; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INSTILLATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERANCE; DYSURIA; FEVER; GASTROINTESTINAL SYMPTOM; HEMATURIA; HUMAN; HYPERSENSITIVITY; LEUKOPENIA; LONG TERM CARE; MEDICAL LITERATURE; MICTURITION DISORDER; NONHUMAN; PH MEASUREMENT; PROPHYLAXIS; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; URINARY URGENCY;

EID: 2642565112     PISSN: 15709124     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1570-9124(03)00020-5     Document Type: Article

References (70)

1. Kiemeney LA, Witjes JA, Heijbroek RP, Verbeek AL, Debruyne FM. Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol 1993;150(1):60-4.
2. Amling CL. Diagnosis and management of superficial bladder cancer. Curr Probl Cancer 2001;25(4):219-78.
3. Kurth KH, Denis L, Bouffioux C, Sylvester R, Debruyne FM, Pavone-Macaluso M, et al. Factors affecting recurrence and progression in superficial bladder tumours. Eur J Cancer 1995;31A(11):1840-6.
4. Holmang S, Johansson SL. Stage Ta-T1 bladder cancer: the relationship between findings at first followup cystoscopy and subsequent recurrence and progression. J Urol 2002;167(4):1634-7.
5. Oosterlinck W, Kurth KH, Schroder F, Bultinck J, Hammond B, Sylvester R. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 1993;149(4):749-52.
6. Solsona E, Iborra I, Ricos JV, Monros JL, Casanova J, Dumont R. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. J Urol 1999;161(4):1120-3.
7. Oosterlinck W, Lobel B, Jakse G, Malmström PU, Stockle M, Sternberg C. Guidelines on bladder cancer. Eur Urol 2002;41(2):105-12.
8. Pycha A, Mian C, Hofbauer J, Haitel A, Wiener H, Marberger M. Does topical instillation therapy influence chromosomal aberrations in superficial bladder cancer? J Urol 1998;159(1):265-9.
9. Groos E, Masters JR. Intravesical chemotherapy: studies on the relationship between osmolality and cytotoxicity. J Urol 1986;136(2):399-402.
10. Tarkington M, Sommers CL, Gelmann EP, Tefft MC, Lynch JH. The effect of PH on the in vitro colony forming ability of transitional cell carcinoma cells treated with various chemotherapeutic agents: implications for in vivo therapy. J Urol 1992;147(2):511-3.
11. Wientjes MG, Badalament RA, Au JL. Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C therapy for superficial bladder cancer. Cancer Chemother Pharmacol 1993;32(4):255-62.
12. Walker MC, Masters JR, Parris CN, Hepburn PJ, English PJ. Intravesical chemotherapy: in vitro studies on the relationship between dose and cytotoxicity. Urol Res 1986;14(3):137-40.
13. Jones HC, Swinney J. ThioTEPA in the treatment of tumours of the bladder. Lancet 1961;II:615-8.
14. Cohen BE, Egorin MJ, Kohlhepp EA, Aisner J, Gutierrez PL. Human plasma pharmacokinetics and urinary excretion of thiotepa and its metabolites. Cancer Treat Rep 1986;70(7):859-64.
15. Masters JR, McDermott BJ, Harland S, Bibby MC, Loadman PM. ThioTEPA pharmacokinetics during intravesical chemotherapy: the influence of dose and volume of instillate on systemic uptake and dose rate to the tumour. Cancer Chemother Pharmacol 1996;38(1):59-64.
16. Soloway MS, Ford KS. Thiotepa-induced myelosuppression: review of 670 bladder instillations. J Urol 1983;130(5):889-91.
17. Thrasher JB, Crawford ED. Complications of intravesical chemotherapy. Urol Clin North Am 1992;19(3):529-39.
18. Richie JP. Intravesical Chemotherapy. Treatment selection, techniques, and results. Urol Clin North Am 1992;19(3):521-7.
19. Bouffioux C, Meijden A, Kurth KH, Jakse G, Bono A, Hall R, et al. Objective response of superficial bladder tumors to intravesical treatment (including review of response of marker lesions). Prog Clin Biol Res 1992;378:29-42.
20. The effect of intravesical thiotepa on tumour recurrence after endoscopic treatment of newly diagnosed superficial bladder cancer. A further report with long-term follow-up of a Medical Research Council randomized trial. Medical Research Council Working Party on Urological Cancer, Subgroup on Superficial bladder cancer. Br J Urol 1994;73(6):632-8.
21. Kurth K, Tunn U, Ay R, Schroder FH, Pavone-Macaluso M, Debruyne F, et al. Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone. J Urol 1997;158(2):378-84.
22. Mufti GR, Virdi JS, Hall MH. Long-term follow-up of intravesical epodyl therapy for superficial bladder cancer. Br J Urol 1990;65(1):32-5.
23. Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, et al. A Randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med 1991;325(17):1205-9.
24. Lamm DL. Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am 1992;19(3):573-80.
25. Rubben H, Lutzeyer W, Fischer N, Deutz F, Lagrange W, Giani G. Natural history and treatment of low and high risk superficial bladder tumors. J Urol 1988;139(2):283-5.
26. Naito S, Kotoh S, Omoto T, Osada Y, Sagiyama K, Iguchi A, et al. Prophylactic intravesical instillation chemotherapy against recurrence after a transurethral resection of superficial bladder cancer: a randomized controlled trial of doxorubicin plus verapamil versus doxorubicin alone. The Kyushu University Urological Oncology Group. Cancer Chemother Pharmacol 1998;42(5):367-72.
27. Akaza H, Isaka S, Koiso K, Kotake T, Machida T, Maru A, et al. Comparative analysis of short-term and long-term prophylactic intravesical chemotherapy of superficial bladder cancer, prospective, randomized, controlled studies of the Japanese Urological Cancer Research Group. Cancer Chemother Pharmacol 1987;20(Suppl):S91-6.
28. Onrust SV, Wiseman LR, Goa KL. Epirubicin: a review of its intravesical use in superficial bladder cancer. Drugs Aging 1999;15(4):307-33.
29. Tsushima T, Miyaji Y, Noda M, Nasu Y, Kumon H, Ohmori H. Absorption of epirubicin instilled intravesically immediately after transurethral resection of superficial bladder cancer. Urol Int 1998;60(3):161-4.
30. Burk K, Kurth KH, Newling D. Epirubicin in treatment and recurrence prophylaxis of patients with superficial bladder cancer. Prog Clin Biol Res 1989;303:423-34.
31. Masters JR, Popert RJ, Thompson PM, Gibson D, Coptcoat MJ, Parmar MK. Intravesical chemotherapy with epirubicin: a dose response study. J Urol 1999;161(5):1490-3.
32. Liu B, Zhang Y, Wang Z, Ding Q, Chen B, Wang J, et al. Single instillation of epirubicin for the prophylaxis of recurrent primary superficial bladder carcinoma. Zhonghua Wai Ke Za Zhi 2002;40(2):112-5.
33. Rajala P, Kaasinen E, Raitanen M, Liukkonen T, Rintala E. Perioperative single dose instillation of epirubicin or interferon-alpha after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter Study-FinnBladder III Long-Term Results. J Urol 2002;168(3):981-5.
34. Okamura K, Murase T, Obata K, Ohshima S, Ono Y, Sakata T, et al. A randomized trial of early intravesical instillation of epirubicin in superficial bladder cancer. The Nagoya University Urological Oncology Group. Cancer Chemother Pharmacol 1994;35(Suppl):S31-35.
35. Eto H, Oka Y, Ueno K, Nakamura I, Yoshimura K, Arakawa S, et al. Comparison of the prophylactic usefulness of epirubicin and doxorubicin in the treatment of superficial bladder cancer by intravesical instillation: a multicenter randomized trial. Kobe University Urological Oncology Group. Cancer Chemother Pharmacol 1994;35(Suppl):S46-51.
36. Kondo T, Onitsuka S, Ryoji O, Kihara T, Goto Y, Satoh T, et al. Analysis of prognostic factors related to primary superficial bladder cancer tumor recurrence in prophylactic intravesical epirubicin therapy. Int J Urol 1999;6(4):178-83.
37. Torelli F, Catanzaro F, Conti G, Comeri CG, Risi O, Pino R, et al. High-dose epirubicin in the prophylactic treatment of T1G2 superficial bladder tumors. Eur Urol 2001;39(Suppl 2):11-4.
38. Okamura K, Kinukawa T, Tsumura Y, Otani T, Itoh H, Kobayashi H, et al. A randomized study of short versus long-term intravesical epirubicin instillation for superficial bladder cancer. Nagoya University Urological Oncology Group. Eur Urol 1998;33(3):285-8.
39. Smith Jr JA, Labasky RF, Cockett AT, Fracchia JA, Montie JE, Rowland RG. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association. J Urol 1999;162(5):1697-701.
40. de Groot AC, Conemans JM. Systemic allergic contact dermatitis from intravesical instillation of the antitumor antibiotic mitomycin C. Contact Dermatitis 1991;24(3):201-9.
41. Pawinski A, Sylvester R, Kurth KH, Bouffioux C, van der Meijden A, Parmar MK, et al. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder cancer. J Urol 1996;156(6):1934-40 [Discussion].
42. Witjes JA, van der Meijden AP, Sylvester LC, Debruyne FM, van Aubel A, Witjes WP. Long-term follow-up of an EORTC randomized prospective trial comparing intravesical Bacille Calmette-Guérin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group. Urology 1998;52(3):403-10.
43. Witjes JA, van der Meijden AP, Witjes WP, Doesburg W, Schaafsma HE, Debruyne FM. A randomised prospective study comparing intravesical instillations of mitomycin C, BCG-Tice, and BCG-RIVM in PTa-PT1 tumours and primary carcinoma in situ of the urinary bladder. Dutch South-East Cooperative Urological Group. Eur J Cancer 1993;29A(12):1672-6.
44. Au JL, Badalament RA, Wientjes MG, Young DC, Warner JA, Venema PL, et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst 2001;93(8):597-604.
45. Fukui I, Kihara K, Sekine H, Tachibana Y, Kawai T, Ishiwata D, et al. Intravesical combination chemotherapy with mitomycin C and doxorubicin for superficial bladder cancer: a randomized trial of maintenance versus no maintenance following a complete response. Cancer Chemother Pharmacol 1992;30(Suppl):S37-40.
46. Huland H, Otto U, Droese M, Kloppel G. Long-term mitomycin C instillation after transurethral resection of superficial bladder carcinoma: influence on recurrence, progression and survival. J Urol 1984;132(1):27-9.
47. Schwaibold H, Klingenberger HJ, Huland H. Long-term results of intravesical prevention of recurrence with mitomycin C and adriamycin in patients with superficial bladder cancer. Urologe A 1994;33(6):479-83.
48. Schwaibold H, Pichlmeier U, Klingenberger HJ, Huland H. Long-term follow-up of cytostatic intravesical instillation in patients with superficial bladder carcinoma. Is short-term, intensive instillation better than maintenance therapy? Eur Urol 1997;31(2):153-9.
49. Krege S, Giani G, Meyer R, Otto T, Rübben H. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guérin. Participating clinics. J Urol 1996;156(3):962-6.
50. Malmström PU, Wijkstrom H, Lundholm C, Wester K, Busch C, Norlen BJ. 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guérin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol 1999;161(4):1124-7.
51. Onrust SV, Lamb HM. Valrubicin. Drugs Aging 1999;15(1):69-75.
52. Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M. Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guérin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol 2000;163(3):761-7.
53. Newling DW, Hetherington J, Sundaram SK, Robinson MR, Kisbenedek L. The use of valrubicin for the chemoresection of superficial bladder cancer - a marker lesion study. Eur Urol 2001;39(6):643-7.
54. Patterson AL, Greenberg RE, Weems L, Bahnson R, Wajsman Z, Israel M, et al. Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer. Urology 2000;56(2):232-5.
55. Lundbeck F, Mogensen P, Jeppesen N. Intravesical therapy of noninvasive bladder tumors (stage Ta) with doxorubicin and urokinase. J Urol 1983;130(6):1087-9.
56. Kobayashi M, Sugaya Y, Yuzawa M, Ochi M, Morita T, Kobayashi Y, et al. Appropriate intravesical retention time of pirarubicin concentration based on its level in tumor tissue, anti-tumor effect and side effect in intravesical instillation therapy for bladder tumor. Gan To Kagaku Ryoho 1998;25(11):1771-4.
57. Okamura K, Ono Y, Kinukawa T, Matsuura O, Yamada S, Ando T, et al. Randomized study of single early instillation of (2″R)-4′-o- tetrahydropyranyl-doxorubicin for a single superficial bladder carcinoma. Cancer 2002;94(9):2363-8.
58. Cozzi PJ, Bajorin DF, Tong W, Nguyen H, Scott J, Heston WD, et al. Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs. Clin Cancer Res 1999;5(9):2629-37.
59. Dalbagni G, Russo P, Sheinfeld J, Mazumdar M, Tong W, Rabbani F, et al. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin- refractory transitional-cell carcinoma of the bladder. J Clin Oncol 2002;20(15):3193-8.
60. Mosher DF. Physiology of fibronectin. Annu Rev Med 1984;35:561-75.
61. Kavoussi LR, Brown EJ, Ritchey JK, Ratliff TL. Fibronectin-mediated Calmette-Guérin bacillus attachment to murine bladder Mucosa. Requirement for the expression of an antitumor response. J Clin Invest 1990;85(1):62-7.
62. Maffezzini M, Simonato A, Zanon M, Raber M, Carmignani G. Up-front intravesical chemotherapy for low stage, low grade recurrent bladder cancer. J Urol 1996;155(1):91-3.
63. Rintala E, Jauhiainen K, Rajala P, Ruutu M, Kaasinen E, Alfthan O. Alternating mitomycin C and bacillus Calmette-Guérin instillation therapy for carcinoma in situ of the bladder. The FinnBladder Group. J Urol 1995;154(6):2050-3.
64. Rintala E, Jauhiainen K, Kaasinen E, Nurmi M, Alfthan O. Alternating mitomycin C and bacillus Calmette-Guérin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer. FinnBladder Group. J Urol 1996;156(1):56-9.
65. Witjes JA, Caris CT, Mungan NA, Debruyne FM, Witjes WP. Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guérin versus mitomycin C alone in patients with superficial bladder cancer. J Urol 1998;160(5):1668-71.
66. Paroni R, Salonia A, Lev A, Da Pozzo LF, Cighetti G, Montorsi F, et al. Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma. Br J Clin Pharmacol 2001;52(3):273-8.
67. Colombo R, Da Pozzo LF, Lev A, Freschi M, Gallus G, Rigatti P. Neoadjuvant combined microwave induced local hyperthermia and topical chemotherapy versus chemotherapy alone for superficial bladder cancer. J Urol 1996;155(4):1227-32.
68. Colombo R, Da Pozzo LF, Lev A, Salonia A, Rigatti P, Leib Z, et al. Local microwave hyperthermia and intravesical chemotherapy as bladder sparing treatment for select multifocal and unresectable superficial bladder tumors. J Urol 1998;159(3):783-7.
69. Nilsson S, Ragnhammar P, Glimelius B, Nygren P. A systematic overview of chemotherapy effects in urothelial bladder cancer. Acta Oncol 2001;40(2-3):371-90.
70. Huncharek M, Geschwind JF, Witherspoon B, McGarry R, Adcock D. Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials. J Clin Epidemiol 2000;53(7):676-80.